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Hearing loss is often caused by death of the mechanosensory hair cells of the inner ear. Hair cells are susceptible to death
caused by aging, noise trauma, and ototoxic drugs, including the aminoglycoside antibiotics and the antineoplastic agent
cisplatin. Ototoxic drugs result in permanent hearing loss for over 500000 Americans annually. We showed previously that
induction of heat shock proteins (HSPs) inhibits both aminoglycoside- and cisplatin-induced hair cell death in whole-organ
culturesofutriclesfromadultmice.Inordertobegintotranslatetheseﬁndingsintoaclinicaltherapyaimedatinhibitingototoxic
drug-induced hearing loss, we have now examined a pharmacological HSP inducer, celastrol. Celastrol induced upregulation of
HSPs in utricles, and it provided signiﬁcant protection against aminoglycoside-induced hair cell death in vitro and in vivo.
Moreover, celastrol inhibited hearing loss in mice receiving systemic aminoglycoside treatment. Our data indicate that the major
heat shock transcription factor HSF-1 is not required for celastrol-mediated protection. HSP32 (also called heme oxygenase-1,
HO-1) is the primary mediator of the protective effect of celastrol. HSP32/HO-1 inhibits pro-apoptotic c-Jun N-terminal kinase
(JNK) activation and hair cell death. Taken together, our data indicate that celastrol inhibits aminoglycoside ototoxicity via
HSP32/HO-1 induction.
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Aminoglycoside antibiotics are among the most commonly
used antibiotics worldwide.
1 Although aminoglycosides are
highly effective antimicrobial agents, their use has serious
side effects, including ototoxicity.
1 Aminoglycoside exposure
results in apoptotic death of the mechanosensory hair cells of
the inner ear.
2–4 Estimates of the incidence of ototoxicity in
individuals undergoing aminoglycoside treatment range from
3to33%.
5Theresulting aminoglycoside-inducedhearingloss
and/or balance disturbance is irreparable.
1
Numerous studies indicate that both reactive oxygen
species (ROS) formation, and activation of c-Jun N-terminal
kinase(JNK)arecriticalmediatorsofaminoglycoside-induced
haircelldeath.
6–8Gentamicinformsaredoxcomplexwithfree
iron, which is capable of catalyzing the formation of ROS,
including the highly reactive hydroxyl radical and lipid
peroxidation products.
8 Evidence for the importance of
oxidative injury in aminoglycoside-induced ototoxicity comes
from studies showing that antioxidants protect hair cells
against aminoglycoside-induced death.
9 A second critical
mediator of aminoglycoside-induced hair cell death is JNK.
7
Inhibition of JNK using either small molecules or cell perme-
able peptides protects hair cells and preserves hearing.
7,10
Although previous clinical studies have demonstrated
protective effects of both salicylate and N-acetylcysteine
against aminoglycoside ototoxicity, there are currently no
co-therapies in widespread clinical use for prevention of
aminoglycoside ototoxicity.
Heat shock proteins (HSPs) are abundant cellular
constituents that function as molecular chaperones, promot-
ing proper protein folding, localization, and function.
11 Induc-
tionofHSPexpressionisahighlyconservedcellularresponse
to stress and injury. HSPs confer robust cytoprotection and
inhibit various apoptotic signaling proteins, making them
potential therapeutic targets for the treatment of a variety of
diseases. Evidence for HSP-mediated protection in the inner
ear initially came from studies in mice exposed to noise
trauma.Totalbodyheatstress(hyperthermia)resultedinHSP
induction and signiﬁcant protection against noise-induced
hearing loss,
12 suggesting that HSP induction can protect
sensory hair cells under stress.
We showed that heat shock inhibits both aminoglycoside-
and cisplatin-induced hair cell death in whole-organ cultures
of utricles from adult mice.
13 HSP70 is necessary for this
protective effect, and constitutive expression of HSP70 is
protective against aminoglycoside-induced hair cell death.
14
Importantly, HSP70 also protects against hearing loss in mice
exposed to systemic kanamycin.
15 Taken together, these
data indicatethatHSP induction isacritical stressresponse in
the inner ear that can promote survival of hair cells exposed to
major stressors. Cisplatin-induced hair cell death is inhibited
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16
HSP32/HO-1 is an enzyme that catalyzes the breakdown of
heme into bilirubin, carbon monoxide (CO), and free iron.
17
Both bilirubin and CO are cytoprotective in the inner ear as
well as in other model systems.
16 Thus, HSP induction may
hold potential as a clinical co-therapy aimed at inhibiting
ototoxic hair cell death and hearing loss.
Methods for inducing the heat shock response in humans
have been available for some time, but these often elicit
inadequate heating of the target area, or they are poorly
tolerated.
18 Therefore, pharmacological induction of HSPs
may be a more clinically feasible approach for protecting cells
under stress. Recently, a consortium of 26 laboratories
cooperated on a screen of the Federal Drug Administration
(FDA)-approved drugs and bioactive compounds in order to
identify compounds that activate the heat shock response.
19
Of these compounds, celastrol was recognized as ‘of
particular interest’ because it was independently identiﬁed in
ﬁve participating laboratories.
19 Celastrol induces HSPs via
activation of the major heat shock transcription factor (Hsf-1).
In addition, celastrol is cytoprotective.
19 Celastrol is a
triterpene compound that is one of several bioactive mole-
cules in extracts from the plant Tripterygium wilfordii. Extracts
from this plant have been used for many years in traditional
Chinese medicine to treat chills, joint pain, and arthritis.
Celastrol has antioxidant and anti-inﬂammatory properties in
addition to being an inducer of the heat shock response.
20
Celastrol is neuroprotective, anti-angiogenic and anti-tumoro-
genic in mouse models.
21 Here we have investigated
celastrol’s potential to inhibit aminoglycoside-induced hair
cell death and hearing loss, and we have examined the
mechanisms underlying the protective effect of celastrol.
Results
Celastrol induces heat shock mRNA and protein
expression. To determine whether celastrol induces HSP
mRNA expression, utricles were incubated in celastrol
(1.5mM) for 3h and allowed to recover in culture medium
for various times. mRNA was analyzed by real-time
quantitative RT-PCR (Figure 1a). Immediately after
incubation in celastrol, HSP70 mRNA levels had increased
to more than 18-fold above control. At 3h post celastrol
incubation, HSP70 levels had decreased to B3-fold above
control, and levels continued to decrease thereafter.
HSP32/HO-1 mRNA levels peaked 3h post celastrol
incubation (B18-fold higher than control expression). mRNA
levels of both HSP27 and HSP90 were slightly elevated by
celastrol. These data indicate that celastrol results in robust
upregulation of HSP70 and HSP32/HO-1 mRNA in utricles.
Western blot analysis was then used to examine celastrol’s
effect on HSP protein levels (Figure 1b). Heat-shocked (431C
for 30min) utricles were used as positive controls for HSP
induction. HSP70 expression levels in celastrol-treated
utricles were comparable to those induced by heat shock.
Celastrol-induced HSP32/HO-1 expression was signiﬁcantly
higher than that in heat-shocked utricles. HSP27 expression
was less than that induced by heat shock but increased
relative to control. HSP90 expression remained relatively
unchanged in both heat-shocked and celastrol-treated
utricles. These data indicate that celastrol induces robust
upregulation of both HSP32/HO-1 and HSP70.
Celastrol inhibits aminoglycoside-induced hair cell
death. Utricles were incubated in celastrol and neomycin,
and Myosin VIIA immunochemistry was used to label
hair cells (Figures 1c–f). Treatment with celastrol alone
(Figure 1d) did not result in hair cell loss relative to utricles
cultured in control media (Figure 1c). Neomycin resulted in
signiﬁcant loss of hair cells (Figures 1e and g). Celastrol
signiﬁcantly attenuated hair cell death induced by neomycin
(Figures 1f and g). We tested celastrol’s protective effect
at a range of neomycin doses (Figure 1g). Celastrol had a
signiﬁcant protective effect against neomycin-induced hair
cell death across the dose–response relationship (2-way
ANOVA F1,132¼28.916, Po0.001).
Celastrol inhibits aminoglycoside-induced JNK activation.
Aminoglycoside-induced hair cell apoptosis is mediated by
JNK.
7,10 In order to begin to examine the mechanisms
underlying the protective effect of celastrol, we studied the
effects of celastrol on JNK activation (Figure 1h). Utricles
were treated with celastrol before treatment with neomycin
for 12h. JNK activation was analyzed using an antibody that
is speciﬁc for dually phosphorylated JNK. Control utricles
displayed little JNK activation. Neomycin resulted in a robust
increase in JNK phosphorylation, and this increase was
inhibited by celastrol. These data indicate that celastrol
inhibits pro-apoptotic JNK signaling in neomycin-exposed
utricles.
Hsf-1 is not required for celastrol’s protective effect.
Celastrol activates the major heat shock transcription factor
Hsf-1,
19 and the protective effect of heat shock against
aminoglycoside-induced hair cell death is dependent on
Hsf-1.
14 To determine whether Hsf-1 is required for the
protective effect of celastrol against aminoglycoside-induced
hair cell death, we utilized utricles from Hsf-1
 /  mice and
their wild-type littermates (Figure 2a). Utricles were cultured
in (1) control media, (2) celastrol, (3) gentamicin, or
(4) celastrol plus gentamicin. Control utricles of both
genotypes had similar hair cell counts. Gentamicin resulted
in signiﬁcant hair cell death in utricles from both Hsf-1
þ/þ
and Hsf-1
 /  mice. Celastrol provided signiﬁcant protection
against gentamicin-induced hair cell death in both Hsf-1
þ/þ
and Hsf-1
 /  utricles (3-way ANOVA F1,59¼34.24,
Po0.001). These data indicate that the protective effect of
celastrol does not require Hsf-1.
Celastrol induces HSP32 expression in the absence of
Hsf-1. As Hsf-1
 /  utricles were protected by celastrol,
we next examined whether celastrol induces HSP expression
in the absence of Hsf-1. HSP70 and HSP32/HO-1
mRNA levels were analyzed in Hsf-1
þ/þ and Hsf-1
 / 
utricles treated with celastrol (Figure 2b). In Hsf-1
þ/þ
utricles, celastrol resulted in B100-fold increase in HSP70
mRNA expression and B17-fold increase in HSP32\HO-1
mRNA. Celastrol did not induce HSP70 in Hsf-1
 / 
utricles. However, celastrol did induce HSP32/HO-1 mRNA
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Cell Death and Diseasein Hsf-1
 /  utricles. Thus, although Hsf-1 is required for
celastrol-mediated induction of HSP70, it is not required for
induction of HSP32/HO-1.
Celastrol induces Nrf2 expression and transcriptional
activation of Nrf2 downstream target genes. Celastrol
can induce expression of cytoprotective antioxidant genes
via activation of the transcription factor Nrf-2 (NF-E2-related
factor-2).
22 In order to determine whether celastrol induces
Nrf2 activation in utricles, explants were incubated in
celastrol and examined for Nrf-2 mRNA levels (Figure 3a).
Celastrol resulted in B3-fold increase in Nrf2 mRNA
expression. Immunocytochemistry was used to examine
Nrf2 expression and cellular localization after celastrol
treatment (Figures 3b–g). In control utricles, Nrf2 was
located primarily in the cytoplasm (Figures 3c and d).
Treatment with celastrol resulted in an increase in total
cellular Nrf2 immunoreactivity as well as an increase in
nuclear Nrf2, suggesting translocation of Nrf2 to the nuclei of
hair cells (Figures 3f and g). In order to further examine
celastrol-mediated Nrf2 activation, we analyzed expression
levels of four other Nrf2 target genes after treatment with
Figure 1 Celastrol induces HSPs and inhibits aminoglycoside-induced hair cell death. (a) RT-PCR analysis of HSP mRNA expression. Utricles were treated with
(or without) celastrol for 3h and allowed to recover for 0–11h. Celastrol resulted in robust upregulation of HSP70 and HSP32/HO-1 mRNA levels relative to control utricles.
MoremodestupregulationofHSP90andHSP27mRNAwereobservedwith celastrol.ErrorbarsrepresentS.E.M.onreal-timeqRT-PCRsperformedintriplicate.(b)Western
blot analysis of celastrol-mediated HSP induction. Utricles treated with a 431C heat shock were used for comparison. Celastrol induced HSP70 expression levels that were
comparable to those induced by heat shock. Celastrol-mediated HSP32 induction was greater than that induced by heat shock. (c and g) Celastrol inhibits aminoglycoside-
induced hair cell death. (c) Control utricles display normal hair cell densities. (d) Celastrol does not decrease hair cell viability. (e) Neomycin results in a signiﬁcant loss of hair
cells. (f) Celastrol inhibits neomycin-induced hair cell death. (g) Celastrol inhibits neomycin-induced hair cell death across the dose–response relationship (2-way ANOVA
F1,132¼28.916, Po0.001). (h) Celastrol inhibits aminoglycoside-induced JNK activation. JNK activation was analyzed by phosphorylation status. Celastrol (1.5mM for 3h)
does not result in JNK activation. Neomycin resulted in robust JNK activation relative to basal levels. Neomycin-induced JNK activation is inhibited by celastrol. Scale bar in
f¼20mM. Asterisks in g denote a signiﬁcant difference in neomycin-induced hair cell death between celastrol-treated and untreated utricles by post hoc tests
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Cell Death and Diseasecelastrol. Nrf2 transcriptionally activates a number of
antioxidant genes, including HSP32/HO-1, glutathione
S-transferase mu 1 (Gstm1), NAD(P)H:quinone oxidoreductase
1 (NQO1), UDP-glucuronosyltransferase (UGT), and gamma-
glutamate cysteine ligase catalytic subunit (GCLC).
23 mRNA
levels of Nrf2 target genes were analyzed in control and
celastrol-treated utricles by quantitative real-time RT-PCR
(Figure 3h). mRNA levels of all four Nrf2 target genes
increased in response to celastrol treatment. These data
provide additional evidence that celastrol activates Nrf2, and
they suggest that celastrol induction of HSP32/HO-1 in the
absence of Hsf-1 may occur through activation of Nrf-2.
HSP32/HO-1 is required for the protective effect of
celastrol. We next investigated the role of HSP32/HO-1 in
celastrol’s protective effect against aminoglycoside-induced
hair cell death by using an HSP32/HO-1 inhibitor, zinc
protoporphyrin IX (ZnPPIX). In order to account for protection
conferred by celastrol-induced HSP70, this experiment was
performed using utricles from both wild-type (HSP70
þ/þ)
and HSP70 knockout (HSP70
 / ) mice. Utricles from mice of
both genotypes were cultured in (1) control media, (2)
celastrol plus ZnPPIX, (3) gentamicin, (4) celastrol plus
gentamicin, or (5) celastrol plus gentamicin and ZnPPIX
(Figure 4a). Culturing utricles in celastrol plus ZnPPIX did not
reduce hair cell viability. Utricles exposed to gentamicin had
signiﬁcant hair cell loss. Celastrol signiﬁcantly inhibited
gentamicin-induced hair cell death in utricles of both
genotypes. The HSP32/HO-1 inhibitor ZnPPIX abolished
celastrol’s protective effect against aminoglycoside-induced
hair cell death in both HSP70
þ/þ and HSP70
 /  utricles
(1-way ANOVA F1,29¼26.35, Po0.0001). These data
indicate that the protective effect of celastrol does not
require HSP70, but it does require HSP32/HO-1.
HSP32/HO-1 inhibits both aminoglycoside-induced hair
cell death and JNK activation. Next we used the HSP32/
HO-1 inducer cobalt protoporphyrin IX (CoPPIX) to examine
whether HSP32/HO-1 induction alone is protective. Utricles
were treated with CoPPIX for 12h before exposure to
neomycin for 24h (Figure 4b). Neomycin resulted in
signiﬁcant hair cell death, which was inhibited by CoPPIX
(2-way ANOVA F1,9¼10.36, Po0.011).
Ourdataindicatethatboth heatshock(datanot shown)and
celastrol inhibit aminoglycoside-induced JNK activation.
CoPPIX was used to determine whether HSP32/HO-1 alone
can inhibit JNK activation. Utricles were incubated in CoPPIX
(20mM) for 12h and then treated with neomycin (Figure 4c).
Control and CoPPIX-treated utricles displayed little JNK
activation (Figure 4c, lanes 1 and 2). Neomycin resulted in a
robust increase in JNK phosphorylation (Figure 4c, lane 3),
whichwasinhibitedbyCoPPIX(Figure4c,lane4).Thesedata
indicate that HSP32/HO-1 alone inhibits pro-apoptotic JNK
signaling in aminoglycoside-treated hair cells. Taken together
with the previous experiments, these data indicate that
HSP32/HO-1 is the major mediator of celastrol-induced
protection.
CO inhibits aminoglycoside-induced hair cell death.
HSP32/HO-1 catalysis of heme results in the production of
CO, which is cytoprotective in a variety of systems.
24 We
utilized the CO donor tricarbonyldichlororuthenium (II) dimer
(CORM2) to further investigate the mechanisms underlying
HSP32/HO-1-mediated protection. Utricles were cultured
in neomycin and CORM2 (Figure 4d). CORM2 provided
signiﬁcant protection against neomycin-induced hair
cell death (1-way ANOVA F1,25¼79.29, Po0.0001),
suggesting that the protective effect of celastrol-induced
HSP32/HO-1 expression may be mediated (at least in part)
by HSP32/HO-1-induced CO production.
Celastrol inhibits aminoglycoside-induced hearing loss
in vivo. Our overall goal is to develop a clinical co-therapy to
inhibit aminoglycoside-induced hearing loss in humans.
Therefore, we next examined celastrol’s effect on hearing
loss caused by systemic aminoglycoside exposure in adult
mice. Hearing thresholds were measured using auditory
brainstem response (ABR) recordings before and after
aminoglycoside treatment. Threshold shifts are reported as
the difference between pretreatment thresholds and post-
treatment thresholds. Thresholds were analyzed for several
frequencies across the normal range of hearing sensitivity in
mice. Mice received either: (1) Celastrol vehicle (cremophor/
PBS, see Materials and Methods for details) and kanamycin
vehicle (saline), (2) Celastrol (plus saline), (3) kanamycin
(plus celastrol vehicle), or (4) Celastrol and kanamycin
(Figure 5, top panel). Mice receiving kanamycin alone had
signiﬁcant hearing loss at all frequencies tested, with mean
threshold shifts ranging from 28dB (at 4kHz) to 63dB
(at 32kHz). Celastrol signiﬁcantly reduced kanamycin-
induced hearing loss (RM-ANOVA, F3,12¼104.77,
Po0.0001, n¼16).
Celastrol inhibits aminoglycoside-induced cochlear hair
cell death in vivo. In order to determine whether celastrol
Figure 2 Hsf-1 isnot requiredfor celastrol-mediated protectionor HSP32/HO-1
induction.(a)UtriclesfromHsf-1
þ/þ andHsf-1
 / miceweretreatedwithcelastrol
(1.5mM for 3h) and/or gentamicin (5mM for 24h). Celastrol did not result in loss of
hair cells in utricles from either Hsf-1
þ/þ or Hsf-1
 /  mice. Gentamicin resulted
signiﬁcant hair cell loss in utricles of both genotypes. Celastrol inhibited gentamicin-
induced hair cell death in both Hsf-1
þ/þ and Hsf-1
 /  utricles (3-way ANOVA
F1,59¼34.24, Po0.001). (b) Celastrol induces HSP32/HO-1 expression in the
absence of Hsf-1. Utricles from Hsf-1
 /  mice and their wild-type littermates were
incubatedincelastrolfor3hbeforeRNAextraction.CelastrolresultedinB100-fold
increase in HSP70 mRNA expression in utricles from Hsf-1
þ/þ mice, but it did not
result in increased HSP70 mRNA in utricles from Hsf-1
 /  mice. In contrast,
celastrol treatment resulted in similar increases in HSP32/HO-1 mRNA levels in
utricles of both Hsf-1
þ/þ and Hsf-1
 /  mice. Error bars represent S.E.M. on real-
time qRT-PCRs performed in triplicate
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Cell Death and Diseaseinhibits cochlear hair cell death caused by systemic
aminoglycoside exposure, cochleas were harvested from
mice after ABR post-testing. Cochleas were dissected into
apical, middle, and basal half-turns. Cochlear hair cells were
labeled using an antibody against Myosin VIIa. A reference
mouse cochlea is shown to demonstrate the normal cochlear
architecture of three rows of outer hair cells and a single row
of inner hair cells (Figure 5, lower panel). Aminoglycoside
damage resulted in a stereotypical gradient of cochlear hair
cell death in which hair cells in the basal turn are more
susceptible to death than hair cells in the apical turn, and
outer hair cells are more susceptible than inner hair cells.
Outer hair cell loss was extensive in all three cochlear turns
of kanamycin-treated mice (Figures 5a–c). The middle and
Figure 3 Celastrol induces Nrf2 activation. (a) RT-PCR analysis of Nrf2 mRNA levels in response to celastrol. Nrf2 mRNA expression peaked after 3h of celastrol
incubation and declined thereafter. Error bars represent S.E.M. on real-time qRT-PCRs performed in triplicate. (b–g) Nrf2 immunolocalization. Hair cell nuclei were labeled
with Hoescht. (b–d) In control utricles Nrf2 is localized to the hair cell cytosol, and the nuclei appear as dark voids (arrows in c). (e–g) Celastrol results in increased Nrf2
immunoreactivity as well as Nrf2 translocation to the nucleus. Scale bar in g¼20mM. (h) qRT-PCR analysis of Nrf2 transcriptional targets. GST, NQO1, UDP, and GGC
expression were all increased in celastrol-treated utricles relative to control levels. Error bars represent S.E.M. on real-time qRT-PCRs performed in triplicate
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Cell Death and Diseasebasal cochlear turns of kanamycin-treated mice showed
complete loss of outer hair cells, while the inner hair cells
remained largely intact (Figures 5b and c). Celastrol
protected outer hair cells in the middle and apical cochlear
turns (Figures 5d and e), but it was not protective in the
basal turn (Figure 5f). These data indicate that celastrol
protects against aminoglycoside-induced cochlear hair cell
death in vivo.
Discussion
We previously showed that HSP induction has a signiﬁcant
protective effect against aminoglycoside-induced hair cell
death.
13–15 Here we have examined the protective effect of
celastrol, a pharmacological inducer of HSPs and antioxidant
genes, against aminoglycoside-induced hair cell death and
hearing loss. Celastrol induced HSP70 and HSP32/HO-1,
and it inhibited aminoglycoside-induced hair cell death
in utricles. Moreover, celastrol inhibited aminoglycoside
ototoxicity in mice receiving systemic kanamycin treatment.
HSP32/HO-1 is both necessary and sufﬁcient for celastrol-
mediated protection.
Celastrol induces HSP32/HO-1 independently of
Hsf-1. Celastrol induces Hsf-1 DNA binding and
hyperphosphorylation, resulting in HSP expression.
19 The
HSP32/HO-1 gene promoter contains a functional Hsf-1-
binding site that results in transcriptional activation in
response to heat shock.
25 Our mRNA and protein
expression analyses indicate that celastrol induces HSP32/
HO-1 and HSP70 expression in utricles. The mechanisms by
which celastrol induces HSP expression remain unclear,
however, gene and protein expression analyses indicate that
celastrol functions as an HSP90 inhibitor.
26 HSP90 inhibitors
are well-known inducers of HSP expression through
derepression of Hsf-1 transcriptional activity.
19,22 However,
our data indicate that Hsf-1 is not required for celastrol-
mediated protection against aminoglycoside-induced hair cell
death. In the absence of Hsf-1, celastrol still induced HSP32/
HO-1 and inhibited hair cell death. This ﬁnding is consistent
with a recent report that HSP32/HO-1 was still induced by
heat shock in the presence of an Hsf-1 inhibitor in cardiac
myocytes.
27
Our data suggest that Hsf-1-independent induction of
HSP32/HO-1 may be mediated by Nrf2, another transcription
factor that can transactivate HSP32/HO-1 expression.
22
Under normal conditions Nrf2 is negatively bound by Keap1
in the cytosol, where it is targeted for ubiquitination and
proteosomal degradation. When exposed to an oxidant or
cellular stress, modiﬁcations in Keap 1 disrupt Nrf2 ubiquitina-
tion, resulting in increased Nrf2 protein levels and transloca-
tiontothenucleus.
28Ourdataindicatethatcelastrolincreases
Nrf2 immunoreactivity and induces Nrf2 translocation to the
nucleus, suggesting activation of Nrf2 transcriptional activity.
Figure 4 HSP32/HO-1 is the major mediator of celastrol’s protectiveeffect. (a) HSP32/HO-1 is required for the protectiveeffect of celastrol. Utricles from both HSP70
 / 
and HSP70
þ/þ mice were treated with celastrol and the HSP32/HO-1 inhibitor ZnPPIX. Gentamicin resulted in signiﬁcant hair cell death in utricles of both genotypes.
Celastrol inhibited gentamicin-induced hair cell death in both HSP70
 /  and HSP70
þ/þ utricles. ZnPPIX abolished the protective effect of celastrol in both HSP70
 /  and
HSP70
þ/þ utricles (1-way ANOVA F1,29¼26.35, Po0.0001). Asterisks indicate signiﬁcance (Po0.05) by post hoc analysis. (b) HSP32/HO-1 inhibits aminoglycoside-
induced hair cell death. Utricles were treated with the HSP32/HO-1 inducer CoPPIX. HSP32/HO-1 induction inhibited aminoglycoside-induced hair cell death (2-way ANOVA
F1,9¼10.36, Po0.011). (c) HSP32/HO-1 inhibits aminoglycoside-induced JNK activation. Neomycin increased JNK activation, and this activation was inhibited by CoPPIX.
(d) CO inhibits aminoglycoside-induced hair cell death. Utricles were treated with CORM2, a CO-releasing molecule. CORM2 partially inhibited neomycin-induced hair cell
death (1-way ANOVA F1,25¼79.29, Po0.0001)
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Cell Death and DiseaseMoreover, celastrol induced mRNA expression of other
Nrf2 target genes. Thus, celastrol-mediated HSP32/HO-1
induction may be via Nrf2 activation.
HSP32/HO-1 is the major mediator of the protective
effect of celastrol. As celastrol is a potent inducer of
HSP32/HO-1, we examined whether HSP32/HO-1 is
required for the protective effect of celastrol. ZnPPIX is a
small molecule inhibitor of HSP32/HO-1 activity.
29 ZnPPIX
abolished celastrol’s protective effect against aminoglyco-
side-induced hair cell death, indicating that HSP32/HO-1 is
required for celastrol-induced cytoprotection. The speciﬁc
mechanisms by which HSP32/HO-1 confers protection are
unclear. Our data using the CO donor CORM2 indicate that
CO inhibits aminoglycoside-induced hair cell death,
suggesting that HSP32/HO-1-mediated CO production may
have a role in celastrol’s protective effect. CO has important
roles in intracellular signaling, and it can protect against
mitochondrial dysfunction and oxidative stress.
30 CO
interacts with Complex IV of the electron transport chain,
inducing a backup of electrons at Complex III, resulting in low
levels of superoxide production. This low-level ROS
production is thought to act as a preconditioning stress for
further insults.
31
Mechanisms of celastrol-mediated protection. Our data
suggest that the protective effect of celastrol occurs via
HSP32-mediated inhibition of JNK activation. The
importance of JNK as a mediator of aminoglycoside-
induced hair cell death has been established by several
studies showing that inhibition of JNK is sufﬁcient to inhibit
aminoglycoside-induced hair cell death and hearing loss.
7,10
The mechanisms by which aminoglycosides activate JNK
Figure 5 Celastrol inhibits aminoglycoside-induced hearing loss and hair cell death in vivo. Top panel: hearing testing via ABR analysis was used to determine whether
celastrol inhibits aminoglycoside-induced hearing loss in vivo. Pre-test ABR thresholds were determined, then mice received daily injections of celastrol and/or kanamycin for
14days.ABRhearingthresholdswereagainmeasured3weeksaftertheﬁnalinjections,anddataarereportedasthresholdshifts(thatis,thedifferencebetweenpre-testand
post-testthresholds).Micetreatedwithkanamycinshowedsigniﬁcanthearinglosses(thresholdshifts)atallfrequenciestested.Micetreatedwithcelastrolpluskanamycinhad
signiﬁcantlysmallerthresholdshiftsthanmicegivenkanamycinalone(RM-ANOVA,F3,12¼104.77,Po0.0001,n¼16).Asterisksindicatesigniﬁcance(Po0.05)byposthoc
analysis. Lower panel: celastrol inhibits aminoglycoside-induced cochlear hair cell death in vivo. Myosin VIIa immunohistochemistry was used to label hair cells in cochleas of
mice treated with kanamycin and celastrol. The normal mouse cochlea (shown for reference) contains a single row of inner hair cells (IHC) and three rows of outer hair cells
(OHC1–3).(a–c)Thecochleaofamousetreatedwithkanamycinshowssomelossofouterhaircellsintheapex(a)andtotallossofouterhaircellsinthemiddle(b)andbase
(c).Occasionallossofinnerhaircellsisalsoevident(b).(dande)Thecochleaofamousetreatedwithkanamycinpluscelastrolretainsofthemajorityofouterhaircellsinthe
apical and middle turns, and all inner hair cells are present. (f) Celastrol did not protect outer hair cells in the basal turn of the cochlea. Scale bar¼30mm
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Cell Death and Diseasesignaling in hair cells are unclear. However, it is well
established that aminoglycoside exposure results in
generation of ROS in hair cells,
6 and data from other
systems indicate that ROS are activators of JNK.
32
Both heat shock and celastrol resulted in induction of
HSP70 and HSP32/HO-1. In addition, both heat shock (data
not shown) and celastrol inhibited aminoglycoside-induced
JNK phosphorylation. HSP70 is a potent inhibitor of JNK
phosphorylation.
33 Therefore, in wild-type mice, HSP70 may
have a role in the protective effect of celastrol against
aminoglycoside-induced ototoxicity via inhibition of JNK
phosphorylation. However, HSP70 is not required for the
protective effect of celastrol, as celastrol was protective in
utricles from both HSP70
 /  and Hsf-1
 /  mice.
Our data suggest that HSP32/HO-1 is both necessary and
sufﬁcient for celastrol-mediated protection. Inhibition of
HSP32/HO-1 using ZnPPIX abolished the protective effect
of celastrol. Moreover, induction of HSP32/HO-1 using
CoPPIX inhibited aminoglycoside-induced JNK activation
and hair cell death. HSP32/HO-1 is associated with increased
antioxidant activity and ROS scavenging via its downstream
products bilirubin and CO.
30 Our data using CORM2 indicate
that CO is protective against aminoglycoside-induced hair cell
death. Therefore, HSP32/HO-1-mediated CO production may
inhibit ROS formation upstream of JNK activation in hair cells.
Taken together, our data are consistent with a model in which
the protective effect of celastrol occurs via Nrf-2-mediated
induction of HSP32/HO-1. HSP32/HO-1 inhibits JNK activa-
tion,possibly viaitsgenerationofCO,whichisitself protective
(Figure 6).
Towards development of a co-therapy to prevent
ototoxic drug-induced hearing loss. Mice treated with
celastrol had signiﬁcantly less hearing loss and more hair cell
survival compared with those treated with kanamycin alone,
suggesting that celastrol may hold potential as a co-therapy
aimed at preventing aminoglycoside-induced hearing loss in
humans. Celastrol is one of several pharmacologically active
compounds in extracts of T. wilfordii, also known as Thunder
of God Vine (lei gong teng in China). Extracts of this vine
have been used for many years in traditional Chinese
medicine.
20 Although puriﬁed celastrol itself has not yet
been studied in clinical trials, there have been several studies
showing the safety and efﬁcacy of extracts of T. wilfordii.
Ethyl acetate extracts of T. wilfordii were entered into phase I
trials in 2001.
34 Doses up to 570mg/day of extract were
well-tolerated, and doses of 360mg/day were associated
with clinical improvement of the symptoms of rheumatoid
arthritis.
34 In another trial, rheumatoid arthritis patients
receiving extracts of T. wilfordii showed greater improve-
ment in symptoms and reduction in inﬂammatory interleukin-6
levels than those receiving sulfasalazine.
35 T. wilfordii extract
also inhibits transplant rejection and renal dysfunction in
kidney transplant patients.
36 Although additional clinical data
are necessary to assess the safety and efﬁcacy of celastrol,
these initial studies suggest that celastrol may be well-
tolerated and effective in humans.
Similar to aminoglycosides, cisplatin is a highly efﬁcacious
drug with signiﬁcant ototoxic side effects. Cisplatin is an
anticancer drug that is widely used to treat a variety of solid
tumors. Induction of HSP32/HO-1 and the products of heme
catalysis,COandbilirubinprotectauditorycellsfromcisplatin-
induced apoptosis.
16 Our unpublished data indicate that
celastrol also attenuates hair cell deathcaused bya moderate
dose of cisplatin. These data suggest that celastrol may also
hold promise as a co-therapy for the inhibition of hearing loss
caused by cisplatin.
In summary, our data indicate that celastrol holds potential
as a clinical co-therapy aimed at preventing aminoglycoside-
inducedototoxicity. Celastrolactivatesboth HSP32/HO-1 and
HSP70. HSP32/HO-1 is the primary mediator of celastrol’s
protective effect.
Materials and Methods
Model system. Our studies utilize whole-organ cultures of utricles from adult
mice. The utricle is a vestibular organ, and the hair cells of the utricle are similar in
both structure and function to the hair cells in the organ of Corti. Adult mammalian
cochlear hair cells do not survive well in vitro using current culture techniques, and
the hair cells of the mouse utricle are sensitive to death from exposure to the same
therapeuticdrugsthatkillcochlearhaircells.
7,37Inaddition,thecellularmechanisms
underlying ototoxic hair cell death and survival are similar for both utricular and
cochlear hair cells.
2,3,15,38 The utricle model system is currently the best-
characterized in vitro preparation for studies of adult mammalian hair cells.
37
Animals. All mice were euthanized by either overdose of Nembutal (Abbot
Laboratories, North Chicago, IL, USA) or CO2 inhalation followed by decapitation.
Utricles were dissected as previously described.
37 Animals were housed in the
central animal care facility at the Medical University of South Carolina, and all
experimental procedures and protocols were approved by the MUSC Institutional
Animal Care and Use Committee.
CBA/JMice. AdultCBA/Jmice(4–6weeksofage)werepurchasedfromHarlan
(Indianapolis, IN, USA) and housed in the MUSC animal care facility.
Hsf-1
 /  mice. Hsf-1
 /  mice were the gift of Dr. Margaret Lomax, who
backcrossed theoriginalHsf-1
 / mice(on themixedgeneticbackgroundC,129X1
(129X1/SvJ BALB/c
39) onto the CBA/CaJ (The Jackson Laboratory, Bar Harbor,
ME, USA) background for at least four generations. At MUSC, the mice were
backcrossed for additional 4–5 generations. Hsf-1
 /  mice were generated by
replacing a 1.8-kb genomic fragment with a 2-kb NEO insert using a gene targeting
vector for Hsf-1.
39 Litters were obtained from heterozygote breeding. Mice were
genotyped 21 days after birth. Tail clips (1mm) were lysed using DirectPCR Lysis
Figure 6 Potential mechanisms of celastrol-mediated protection against
aminoglycoside-induced hair cell death. Aminoglycoside antibiotics result in
increased ROS production and pro-apoptotic JNK activation in hair cells. Celastrol
activates the Nrf2-transcription factor and induces HSP32/HO-1. HSP32/HO-1
inhibits pro-apoptotic JNK activation and hair cell death, possibly through the action
of CO
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Cell Death and DiseaseReagent (Viagen Biotech 101-T, Los Angeles, CA, USA). Crude DNA from tail
lysates was used in one-step PCR genotyping (TaqMan Core Reagent Kit, Applied
Biosystems N808-0228, Foster City, CA, USA; Mastercycler, Eppendorf 5333,
Hamburg, Germany). Primers were as follows: Forward Hsf-1 primer 50-A
GACCTGTCCTGTGTGCCTAGC-30, reverse Hsf-1 primer 50-CAGTTCA
ACTGCCTACACAGACC-30, yielding a 562-bp product of the Hsf-1 gene; forward
NEO primer 50-AAGTATCCATCATGGCTGATGC-30, reverse NEO primer
50-TAGCCAACGCTATGTCCTGATA-30, yielding a 339-bp product of the inserted
NEO gene.
HSP70.1/3
 /  mice. HSP70.1/3
 /  mice were obtained from the Mutant Mouse
Regional Resource Center at the University of California, Davis. HSP70.
1/3
 /  mice have a targeted deletion of both HSP70.1 and HSP70.3.
40 Both
genes are on mouse chromosome 17 separated by 11kb of genomic DNA. This
fragmenthas beenreplacedby a3.1-kbneogene,drivenbytheRNApolymeraseII
promoter. These mice are on a mixed C57BL/6 129SvJ background, and
homozygote knockouts are viable and fertile. Thus, litters were obtained through
homozygote breeding. Wild-type B6/129SF2 mice were purchased from the
Jackson Laboratory and used as strain controls.
Utricle cultures. Utricles from adult mice were dissected under sterile
conditions and cultured free-ﬂoating (4–6 utricles/well) in 24-well tissue culture
platesas previously described.
37 Culture medium consisted of Basal MediumEagle
(Sigma, St. Louis, MO, USA) supplemented with Earle’s Balanced Salt Solution
(Invitrogen, Carlsbad, CA, USA) (2:1 v/v), 5% fetal bovine serum (Invitrogen) and
50U/ml penicillin G (Sigma). Utricles pretreated with celastrol (Calbiochem, San
Diego, CA, USA) were incubated in 1.5mM celastrol in culture medium for 3h and
allowed to recover in culture medium for 5h. Following recovery, CBA/J utricles
were exposed to varying concentrations of neomycin (1–5mM) (Sigma) in culture
medium in an incubator at 371C and 5% CO2 for 24h. Neomycin is not toxic to hair
cells from Hsf-1
 /  and HSP70.1/3
 /  mice because these knockout strains
contain a neomycin resistance gene (Neo), which has been inserted into the target
gene locus.
39,40 The Neo gene encodes an aminoglycoside kinase class-II enzyme
(APH(30)-II), which modiﬁes neomycin, kanamycin, and other aminoglycosides at
the 30-hydroxyl group. Gentamicin lacks this functional group and therefore is not a
substrateforAPH(30)-II.
41UtriclesfromHsf-1
 / andHSP70.1/3
 / micewerepre-
treated with celastrol for 3h and allowed to recover for 5h before being exposed to
5mM gentamicin sulfate (Sigma) in culture medium, for 24h at 371C and 5% CO2.
ZnPPIX. Utricles from HSP70.1/3
 /  or HSP70.1/3
þ/þ mice were pretreated
with celastrol for 3h and allowed to recover for 5h before being exposed to 5mM
gentamicin sulfate (Sigma) in culture medium, for 24h at 371C and 5% CO2. Some
utricles were maintained in the HSP32 inhibitor ZnPPIX (10mM) (Frontier Scientiﬁc,
Logan, UT, USA) for the entire culture period.
CoPPIX. UtriclesfromCBA/JmicewerepretreatedwiththeHSP32/HO-1inducer
CoPPIX (20mM) (Frontier Scientiﬁc) for 12h before being exposed to 2mM
neomycin in culture medium for 12h at 371C and 5% CO2.
Tricarbonyldichlororuthenium (II) dimer. Utricles from CBA/J
mice were co-cultured with the CO donor tricarbonydichlororuthenium (II) dimer
(50mM) (Sigma) and 2mM neomycin sulfate in culture medium for 24h at 371C
and 5% CO2.
Western blot analyses. Utricles (8–10 per condition) were homogenized in
RIPAcelllysisbuffer(150mMNaCl,1mMethylenediaminetetraaceticacid (EDTA),
1% NP-40, 0.25%. Na deoxycholate, 0.1% SDS, and 1mM NaVO4 in PBS)
supplemented with Protease Inhibitor Cocktail Set III 10mM (Calbiochem). Protein
lysates were subjected to SDS-PAGE using 4–15% Tris–HCl gels (Bio-Rad,
Hercules, CA, USA), then transferred onto PVDF membranes (Millipore, Billerica,
MA, USA). Primary antibodies for HSP90, HSP70, HSP32 and HSP27 (Cell
Signaling, Danvers, MA, USA; 1:1000), and secondary antibodies, Immun-Star
Goat Anti-Mouse-HRP Conjugate (#170–5047, Bio-Rad 1:2000) and Immun-Star
Goat Anti-Rabbit-HRP Conjugate (#170–5046, Bio-Rad 1:2000), were diluted in
blocking solution, consisting of 5% milk (Bio-Rad). PVDF membranes were
incubatedinprimaryantibodiesovernightat41Candsecondaryantibodiesfor1–2h
at room temperature. Signal ampliﬁcation and visualization were achieved
using chemiluminescence (SuperSignal West Dura Extended Duration Substrate)
using pre-ﬂashed CL-XPosure Film (Pierce Biotechnology, Rockford, IL, USA).
Each experiment was repeated 2–4 times with similar results, and a representative
blot is shown.
JNK assays. JNK1 and JNK2/3 phosphorylation were analyzed by western blot
using a phosphorylation-state speciﬁc JNK antibody (# 9255S, Cell Signaling) that
speciﬁcally recognizes threonine
183 and tyrosine
185-phosphorylated JNK1 and
JNK2/3. After blotting, blots were stripped using Re-Blot Plus Strong Antibody
Stripping Solution (Millipore) and re-probed with a total JNK antibody, which
recognizes equally well the phosphorylated and non-phosphorylated forms of JNK
(#9258, Cell Signaling). There are three JNK genes (JNK1, JNK2, JNK3), each of
which undergoes alternative splicing to yield multiple isoforms. Each of the
antibodies used is expected to yield three bands, corresponding to the 46kDa and
52kDa forms of JNK 1, and the 54kDa form of both JNK2 and JNK3. Each
experiment was repeated twice with similar results, and a representative blot is
shown.
Real-time quantitative RT-PCR. For analysis of celastrol-induced changes
in mRNA expression, utricles (three per condition) were incubated in 1.5mM.
celastrol for 3h and allowed to recover for 0, 3, 5, 8, or 11h in culture medium.
Control and celastrol-treated utricles were stored in RNAlater RNA Stabilization
Reagent (Qiagen, Valencia, CA, USA). Utricles were homogenized in a ground
glass homogenizer (Wheaton Science, Millville, NJ, USA), and total RNA was
collectedusingRNeasyMicro(Qiagen).RNAwasreversetranscribedusingrandom
hexamer primers (TaqMan, Applied Biosystems), and the resulting cDNA was used
for SYBR Green (Applied Biosystems) real-time PCR ampliﬁcation of HSP70,
HSP32, HSP90, HSP27, Nrf2, Gstm1, NQO1, UGT, and GCLC. Primer sets are
detailed in Table 1. All mRNA analyses were performed in triplicate, and results are
reported as fold changes in mRNA levels relative to control (untreated) utricles for
each triplicate (mean±S.E.M.).
Hair cell counts. A double-label immunochemistry protocol using calmodulin
and calbindin was used for quantiﬁcation of hair cell density by epi-ﬂuorescence
microscopy, as previously described.
13 In addition anti-Myosin VIIa labeling of
utricles was used to determine hair cell density by confocal microscopy. Cultured
utricles were ﬁxed in 4% paraformaldehyde overnight at 41C. After ﬁxation utricles
were washed in 0.1M Sorenson’s Phosphate Buffer (40mM Na2HPO4/95mM
NaH2PO4; pH 7.4) at room temperature. Otoconia were removed using Cal-Ex
(Fisher Scientiﬁc, Pittsburg, PA, USA) for 2min at room temperature followed by
washes with 0.1M Sorenson’s Phosphate Buffer. Utricles were then treated for
Table 1 Primer sets used for quantitative real-time PCR analyses
Gene Forward primer Reverse primer
HSP70 50-AGGCCAGGGCTGGTATTACT-30 50-AATGACCCGAGTTCAGGATG-30
HSP32 50-CTCACAGATGGCGTCACTTCGTCA-30 50-TTGCCAACAGGAAGCTGAGA-30
HSP90 50-GTGCGTGTTCATTCAGCCAC-30 50-GCAATTTCTGCCTGAAAGGC-30
HSP27 50-GAGAACCGAACGACCGTCC-3 50-CCCAATCCTTTGACCTAACGC-30
Nrf2 50-CAGTCTTCACTGCCCCTCAT-30 50-TCTGTCAGTGTGGCTTCTGG-30
Gstm1 50-CCTATGATACTGGGATACTGGAACG-30 50-GGAGCGTCACCCATGGTG-30
NQO1 50-GCAGGATTTGCCTACACAATATGC-30 50-AGTGGTGATAGAAAGCAAGGTCTTC-30
UGT 50-GAAGCCTATGTCAACGCC-30 50-GCATCATCACCATCGGAA-30
GCLC 50-ATCCTCCAGTTCCTGCACAT-30 50-TGTGAATCCAGGGCA-30
18s 50-TTCGGAACTGAGGCCATGATT-30 50-TTTCGCTCTGGTCCGTCTTG-30
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Cell Death and Disease10min at room temperature with 1% sodium borohydride (Sigma). Utricles were
washedagainin0.1MSorenson’sPhosphateBuffer,followedbya3-hincubationin
blocking solution (0.5% ﬁsh gelatin/1% bovine serum albumin/0.5% Triton X-100 in
PBS). Anti-Myosin VIIa (MYO7A 138-1 from the Developmental Studies Hybridoma
Bank, Iowa City, IA, USA; 1:80) was diluted in blocking solution. Utricles were
incubated in primary antibody overnight at 41C, followed by washes with blocking
solution.Utricles werethenincubatedinAlexa488-conjugated goatanti-mouseIgG
(Invitrogen; 1:500) diluted in blocking solution for 3h in the dark at room
temperature.Utricleswerewashedagaininblockingsolutionandmountedon glass
slides using Fluoromount-G (Southern Biotech, Birmingham, AL, USA). Utricles
were visualized using a Zeiss Axioplan 2 epi-ﬂuorescent microscope (Carl Zeiss
Microimaging, Thornwood, NY, USA), and images were captured using a high-
resolution monochrome digital camera (Zeiss Axiocam MR) and imaging software
(Zeiss AxioVision). Hair cell counts were performed as previously described.
13
Brieﬂy, hair cells were counted in each of 4–5 extrastriolar 900mm
2 areas. These
counts were averaged for each utricle and reported as hair cell densities (hair cells
per unit area). Some utricles were imaged using a Zeiss LSM 510 LSCM equipped
with a  63 oil objective and  2 digital zoom.
Wholemountcochleahalf-turns. Cochlearhaircellswerelabeledusinga
protocol described previously by Taleb et al.
15 Cochleas were removed and
perfused with ice cold 4% paraformaldehyde for ﬁxation. After perfusion, cochleas
were further incubated in 4% paraformaldehyde for 2h at room temperature. After
ﬁxation cochleas were washed for 30min in PBS before incubation in 0.5M EDTA
with stirring for 3 days at room temperature. Cochleas were washed with PBS and
bisected along the mid-modiolar plane using a piece of single-edge razor blade
secured in a hemostat. All of the subsequent steps were carried out at 41Co na
nutator. Cochlear halves were incubated in 30% hydrogen peroxide/water/PBS/
methanol at a ratio of 1/3/5/1 for 2.5h to quench endogenous peroxidases.
Cochleas were then incubated in blocking solution (2% bovine serum albumin/0.8%
normal goat serum/0.4% Triton-X in PBS) overnight. Cochleas were incubated for
4 days with a polyclonal anti-Myosin VIIa antibody (Proteus BioSciences Inc.
#25–6790, Ramona, CA, USA; 1:30 diluted in blocking solution) to label hair cells.
Cochleas were next washed with blocking solution for 4h. Biotinylated goat anti-
rabbit secondary antibody (Vector Laboratories Inc. #PK-4001, Burlingame, CA,
USA) was diluted 1:100 in blocking solution and cochleas were incubated
overnight. Following secondary antibody incubation, cochleas were washed with
PBS and then incubated in ABC (Vector Labs #PK-4001) overnight. After washing,
cochleas were incubated in buffer (Vector Laboratories Inc. #SK-4100) for 20min
before incubation in diaminobenzidine (Vector Laboratories Inc. #SK-4100) for 6h.
Cochleas were then washed once more in PBS before the ﬁne tissue preparation.
A microscalpel and iridectomy scissors were used to dissect cochlear halves into
apical, middle, and basal half-turns. The osseous spiral lamina, modiolus, stria
vascularis, and tectorial membrane were removed, and cochlear half-turns were
mounted on glass slides using Fluoromount-G.
Nrf2 localization. Utricles were cultured as above and exposed to 1.5mM.
celastrol for 3h and allowed to recover for 3h. Control utricles were maintained in
culture medium. Utricles were then ﬁxed in 4% paraformaldehyde for 1h at room
temperature, followed by three washes in PBS and 3h in blocking solution at room
temperature. The tissue was incubated in primary antibody against Nrf2 (abCam
#31163;1:100),dilutedinblockingsolution,overnightat41C.Utricleswerewashed
three times in blocking solution before being incubated in Alexa 488-conjugated
goat anti-rabbit IgG (Invitrogen; 1:500) for 3h at room temperature. Utricles were
washed again in blocking solution, and incubated in Hoechst (Millipore; 1.25mg/ml)
for 5min at room temperature to label nuclei. Utricles were mounted as above.
Confocal images were obtained using a Zeiss 510 META LSCM. Identical settings
for pinhole size, gain, offset, and zoom were used for imaging utricles. For each of
twoexperiments,ﬂuorescenceintensityfromﬁverandomhaircellsineachcondition
(nuclei and whole cells) was quantiﬁed using Adobe Photoshop.
Systemic celastrol and kanamycin treatments. A reliable protocol for
aminoglycoside-induced hearing loss in mice has been established using the
aminoglycoside kanamycin.
42 Celastrol was dissolved in DMSO at a concentration
of 10mg/ml. Mice received an initial injection of celastrol (4mg/kg of body weight,
i.p.) diluted in 0.25ml of vehicle (40% cremophor/ethanol 3:1; 60% PBS), 12h
beforetheﬁrstkanamycininjection.Controlmicereceivedvehiclealone.Kanamycin
was purchased from USB Corporation (Cleveland, OH, USA). Manufacturer’s
speciﬁcations estimated the purity of kanamycin base at 76.5%, after correction for
water and sulfate. Kanamycin powder base was dissolved in 0.9% sterile sodium
chloride (saline) (Hospira, Lake Forest, IL, USA) to get a solution of concentration
52.3mg/ml. This concentration allowed 800mg/kg of kanamycin (adjusted for water
and sulfate) to be delivered subcutaneously to each animal at 0.02ml/g of body
weight. Control mice received saline alone. After the initial celastrol injection, mice
were administered once daily injections of celastrol (or vehicle) each morning,
followedimmediatelybyaninjectionofkanamycin(orsaline). At8hafterthemorning
injections, mice received an additional kanamycin injection, totaling three daily
injections (one celastrol and two kanamycin) for each of 14 days.
42 In general, mice
tolerated both celastrol and kanamycin, although one animal receiving kanamycin
expired. ABR post-test analysis was performed 3 weeks after the ﬁnal injection.
Auditory brainstem response. ABRs of adult CBA/J mice were recorded
before receiving injections of celastrol and kanamycin. Mice were anesthetized with
an intraperitoneal injection of 100mg/kg ketamine hydrochloride (Fort Dodge
Animal Health, Dodge, IO, USA) and 2mg/kg xylazine hydrochloride (Ben Venue
Laboratories,Bedford,OH,USA).Allrecordingswereperformedinasound-isolated
chamber, and mice were placed on a warming pad (Deltaphase Isothermal Pad,
Braintree Scientiﬁc, Braintree MA, USA) to maintain body temperature. ABR testing
equipment was purchased from Intelligent Hearing Systems (Miami, FL, USA).
ABR recordings were captured by subdermal needle electrodes (FE-7 Grass
Technologies, West Warwick, RI, USA) placed as follows: (1) non-inverting
electrode atthevertexofthemid-line,(2)invertingelectrode overthemastoidof the
right ear, and (3) the common electrode on the upper thigh. Stimulus tones were
presented at a rate of 19.3/s in free ﬁeld via a high-frequency transducer (Intelligent
Hearing Systems).Responseswere ﬁltered at 300–3000Hz. Stimulusintensity was
decreased in 10dB steps until a response waveform could no longer be identiﬁed.
Subsequently stimulus intensity was increased in 5dB steps until a waveform could
again be identiﬁed. Suprathreshold responses were used as a comparison for
determination of the threshold response. Threshold levels were determined from
1024 stimulus presentations, for at least two trials, and all thresholds were
determined by a certiﬁed audiologist. Animals showing no response to stimulus
presentations at the maximum output limits of the transducer were assigned
threshold values of 5dB greater than the output limit of the equipment. All animals
were euthanized without recovery from anesthesia after ﬁnal post-test completion.
Statistical analyses. Data were analyzed by ANOVA with Tukey’s multiple
comparisons for post hoc tests. P-values o0.05 were considered statistically
signiﬁcant. All error bars represent ±standard error of the mean (S.E.M).
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